Glen Rock, N.J, Feb. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), a leader in the research and development of cannabinoids for the treatment of sleep-related breathing disorders, is pleased to announce the unanimous appointment on January 28, 2020, of Tim Jones as a member of its board of directors to fill a vacancy. Tim Jones is a highly experienced biopharmaceutical industry veteran with an outstanding track record in strategic commercial and business development, specializing in developing and sustaining high value strategic partnerships. He brings over 25 years of pharmaceutical industry experience across multiple disciplines and global markets. During the last three years, Tim has been a senior member of the management team at Noramco Inc. that created an industry-leading cannabinoids business. This business was spun off as Purisys, LLC which focuses on cannabinoids for pharmaceutical and consumer products. Mr. Jones currently serves as Vice President Global Pharmaceutical and Medical OTC for Purisys, focusing on the development of long-term strategic partnerships and customer relationships.

Tim’s experience includes 15 years of API (active pharmaceutical ingredient) sales, business development, and sourcing in the niche, controlled substances space. He is recognized in the industry for his expertise in the strategic development and growth of active pharmaceutical ingredient categories, through partnerships with a broad cross section of brand and generic companies worldwide. Tim’s extensive knowledge base and expertise across multiple pharmaceutical disciplines, have all contributed to his successful track record of financial growth. He previously held leadership roles with QuVa Pharma, Par Sterile Products, and Johnson Matthey. “Few people have the overall experience in the cannabinoid business that Tim does. During the last three years at Noramco, Inc. and now Purisys LLC, Tim’s strategic commercial and business development acumen was instrumental in driving their expansion into one of the world’s largest synthetic cannabinoid manufacturers,” said Dr. Arnold Lippa, Executive Chairman, Interim CEO and Interim President and Chief Scientific Officer of RespireRx.

“My appointment to the RespireRx Board of Directors coincides with the company’s exciting new market strategy addressing the broader cannabinoids pharmaceutical space, not only in the field of sleep apnea, but across a farther reaching portfolio of prescription products, driven by our unique IP position and the intrinsic value stream anticipated from this core strength. My personal expertise in the global cannabinoids pharma sector, partnered with a focused company vision, steered by a seasoned team of professionals, makes RespireRx highly attractive for further strategic investment and sets the stage for a very bright future,” said Tim Jones.

About RespireRx Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. is a leader in the development of medicines for respiratory disorders and CNS indications, with a focus on obstructive sleep apnea, attention deficit hyperactivity disorder (ADHD), spinal cord injury and other neurological conditions. The Company holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.